Depo-Medrol Indications/Uses

For Intramuscular Administration: When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone acetate (Depo-Medrol) Sterile Aqueous Suspension is indicated as follows: Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).
Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used).
Congenital adrenal hyperplasia; Hypercalcemia associated with cancer; Non-suppurative thyroiditis.
Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis; Epicondylitis; Synovitis of osteoarthritis; Acute non-specific tenosynovitis; Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); Psoriatic arthritis; Acute gouty arthritis; Ankylosing spondylitis; Acute and subacute bursitis.
Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus; Systemic dermatomyositis (polymyositis); Acute rheumatic carditis.
Dermatologic Diseases: Pemphigus; Bullous dermatitis herpetiformis; Severe erythema multiforme (Stevens-Johnson syndrome); Severe seborrheic dermatitis; Exfoliative dermatitis; Mycosis fungoides; Severe psoriasis.
Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma; Drug hypersensitivity reactions; Contact dermatitis; Urticarial transfusion reactions; Atopic dermatitis; Acute non-infectious laryngeal edema (epinephrine is the drug of first choice); Serum sickness.
Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus; Drug hypersensitivity reactions; Iritis, iridocyclitis; Anterior segment inflammation; Chorioretinitis; Allergic conjunctivitis; Diffuse posterior uveitis; Allergic corneal marginal ulcers; Optic neuritis; Keratitis.
Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy); Regional enteritis (systemic therapy).
Respiratory Diseases: Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculous chemotherapy; Symptomatic sarcoidosis; Berylliosis; Loeffler's syndrome not manageable by other means; Aspiration pneumonitis.
Hematologic Disorders: Acquired (autoimmune) hemolytic anemia; Erythroblastopenia (RBC anemia); Secondary thrombocytopenia in adults; Congenital (erythroid) hypoplastic anemia.
Neoplastic Diseases: For palliative management of: Leukemias and lymphomas; Acute leukemia of childhood.
Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy; Trichinosis with neurologic or myocardial involvement.
For Intra-synovial or Soft Tissue Administration (including peri-articular and intrabursal) (see Precautions): Methylprednisolone acetate (Depo-Medrol) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis; Epicondylitis; Rheumatoid arthritis; Acute non-specific tenosynovitis; Acute and subacute bursitis; Post-traumatic osteoarthritis; Acute gouty arthritis.
For Intralesional Administration: Methylprednisolone acetate (Depo-Medrol) is indicated for intralesional use in the following conditions: Keloids, Localized hypertrophic, infiltrated, inflammatory lesions of: Lichen planus, psoriatic plaques; Discoid lupus erythematosus; Necrobiosis lipoidica diabeticorum; Granuloma annulare; Lichen simplex chronicus (neurodermatitis); Alopecia areata.
Methylprednisolone acetate (Depo-Medrol) may also be useful in cystic tumors or an aponeurosis or tendon (ganglia).
For Intrarectal Instillation: Ulcerative colitis.